Bergapten
CAS 484-20-8
Bergapten (CAS 484-20-8) is a Phase 3 pharmaceutical compound with 4 bioactivity targets and 0 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | GI50 | 96319.18894736841 nM | 57 | - |
| - | AC50 | 27738.21875 nM | 32 | - |
| - | IC50 | 18687.94 nM | 22 | - |
| - | Potency | 24663.794444444444 nM | 16 | - |
| - | IC50 | 15.6325 ug.mL-1 | 4 | - |
| - | Ki | 4040 nM | 3 | - |
| - | EC50 | 0.354 ug.mL-1 | 1 | - |
| - | Kd | 41000 nM | 1 | - |
| Amine oxidase [flavin-containing] A Enzyme |
IC50 | 4.86 | - | Homo sapiens |
| Dual specificity tyrosine-phosphorylation-regulated kinase 1A Kinase |
AC50 | 5.83 | - | Rattus norvegicus |
| Cytochrome P450 1A1 Enzyme |
Ki | 7.22 | - | Homo sapiens |
| Taste receptor type 2 member 10 GPCR |
EC50 | 5.55 | - | Homo sapiens |
IUPHAR Ligand-Target Data
Curated ligand-target interaction rows with action, affinity, and literature identifiers.
| Target | Action | Affinity | PubMed |
|---|---|---|---|
| TAS2R10 TAS2R10 |
Agonist | 5.550000190734863 pEC50 | 26501253 |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Bergapten used for in pharmaceutical contexts?
Bergapten (CAS 484-20-8) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Bergapten?
No adverse-event association or SIDER side-effect rows are rendered for Bergapten in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Bergapten also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Bergapten with EU status "restricted".
What clinical phase is Bergapten in?
Bergapten is rendered with ChEMBL max phase 3.
What bioactivity targets are documented for Bergapten?
Bergapten has 12 bioactivity rows in this page query. Rendered target entries include Amine oxidase [flavin-containing] A, Dual specificity tyrosine-phosphorylation-regulated kinase 1A, Cytochrome P450 1A1, Taste receptor type 2 member 10.